See more : Western Atlas Resources Inc. (PPZRF) Income Statement Analysis – Financial Results
Complete financial analysis of IMARA Inc. (IMRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IMARA Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Movie Games S.A. (MOV.WA) Income Statement Analysis – Financial Results
- Siegfried Holding AG (SGFEF) Income Statement Analysis – Financial Results
- Torq Resources Inc. (TORQ.V) Income Statement Analysis – Financial Results
- Multi Retail Group Ltd (MRG.TA) Income Statement Analysis – Financial Results
- Dom Development S.A. (DOM.WA) Income Statement Analysis – Financial Results
IMARA Inc. (IMRA)
About IMARA Inc.
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 18.94M | 38.44M | 32.15M | 19.01M | 8.24M |
| General & Administrative | 15.33M | 13.00M | 9.54M | 5.11M | 2.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.33M | 13.00M | 9.54M | 5.11M | 2.44M |
| Other Expenses | -97.00K | -175.00K | -145.00K | 75.00K | 0.00 |
| Operating Expenses | 34.27M | 51.44M | 41.70M | 24.12M | 10.68M |
| Cost & Expenses | 34.27M | 51.44M | 41.70M | 24.12M | 10.68M |
| Interest Income | 943.00K | 233.00K | 483.00K | 578.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -69.39M | 99.00K | 97.00K | 33.00K | -660.00K |
| EBITDA | -68.66M | -51.34M | -41.60M | -24.08M | -11.34M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 730.00K | -51.44M | -41.70M | -24.12M | -10.68M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 846.00K | 58.00K | 338.00K | 653.00K | -660.00K |
| Income Before Tax | 1.58M | -51.38M | -41.36M | -23.46M | -11.34M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 88.00K | -233.00K | -483.00K | -578.00K | 0.00 |
| Net Income | 1.58M | -51.15M | -40.88M | -22.89M | -11.34M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.24 | -9.45 | -11.74 | -9.69 | -1.20 |
| EPS Diluted | 0.24 | -9.45 | -11.74 | -9.69 | -1.20 |
| Weighted Avg Shares Out | 6.57M | 5.42M | 3.48M | 2.36M | 9.44M |
| Weighted Avg Shares Out (Dil) | 6.57M | 5.42M | 3.48M | 2.36M | 9.44M |
Imara, Inc. (IMRA) CEO Rahul Ballal on Q4 2020 Results - Earnings Call Transcript
Imara, Inc. (IMRA) CEO Rahul Ballal on Q4 2020 Results - Earnings Call Transcript
Imara Reports Full Year 2020 Financial Results and Business Highlights
Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia
Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights
BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host...
Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that Rahul Ballal, Ph.D., President...
Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer
Brings 30 years of medical research experience within the biopharmaceutical industry, including Acceleron Pharma and Genentech Brings 30 years of medical research experience within the biopharmaceutical industry, including Acceleron Pharma and Genentech
Imara Analyst Says Buy The Weakness Ahead Of Multiple 2021 Data Readouts
Imara Inc (NASDAQ: IMRA) shares took a thrashing Wednesday following the release of mid-stage results of its IMR-687 in sickle cell disease. Underwhelming Data: IMR-687 failed to close part of the gap from the 1.7% absolute increase in fetal hemoglobin,...
Imara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
Preliminary data as of August 2020 from ongoing Phase 2a o pen l abel e xtension trial s howed increase s in HbF percentage and F-cell s after approximately six months of treatment
Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that clinical data from the ongoing...
Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory
Brings 25 years of experience in the pharmaceutical and biotech industries and a deep understanding of global regulatory strategy and commercial regulatory affairs Brings 25 years of experience in the pharmaceutical and biotech industries and a deep understanding of global...
IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q3 2020 Results - Earnings Call Transcript
IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q3 2020 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports